Michael Barbella, Managing Editor05.28.24
Outset Medical Inc. is teaming up with U.S. Renal Care to help accelerate home hemodialysis in the United States.
Studies show patients with end-stage kidney disease (ESKD) are healthier mentally and physically dialyzing at home, more likely to be employed and maintain more control of their daily activities. Yet, just 3% of the ESKD population currently performs home hemodialysis, in large part due to historically complicated systems that made it too difficult to undertake or sustain. Under the multi-year agreement, U.S. Renal Care can utilize Outset’s Tablo Hemodialysis System as a home dialysis option throughout the 33 states in which it provides care. Patients dialyzing with Tablo report that the system is easy to learn and operate in their home. Expanding treatment options in the communities served by U.S. Renal Care will aid in meeting the growing demand of dialysis patients seeking treatment at home.
"Our collaboration with U.S Renal Care is an important step forward in providing dialysis patients with options for where, when and how they want to dialyze.” Outset Medical Board Chair/CEO Leslie Trigg said. “Tablo was specifically designed to reduce the complexity of dialysis and help restore the identity and agency of patients who must dialyze to survive. We are pleased to partner with U.S. Renal Care to advance this mission.”
Tablo is indicated for use from the hospital to the home and aims to transform the dialysis experience for patients and operationally simplify it for providers. Requiring only access to tap water and a standard electrical outlet, Tablo serves as a single enterprise solution that can be utilized across the continuum of care, allowing dialysis to be delivered anytime, anywhere and by anyone.
“We strive to provide patients with new and innovative solutions that deliver the best outcomes possible,” U.S. Renal Care Co-Chief Operating Officer Steve Nottingham stated. “We have seen success using the Tablo system in our home hemodialysis program, and with our multi-year agreement with Outset, can continue providing our patients and caregivers access to lifesaving dialysis treatment in an easy-to-operate system, all in the comfort of their own homes.”
U.S. Renal Care, the largest privately held and fastest-growing U.S. dialysis provider, partners with nephrologists across 500 centers in 33 states to care for thousands of people living with kidney disease nationwide.
Outset Medical is a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis. The Tablo Hemodialysis System, cleared by the U.S. Food and Drug Administration for use from the hospital to the home, serves as a single enterprise solution that can be used across the continuum of care, allowing dialysis to be delivered anytime, anywhere and by anyone. The integration of water purification and on-demand dialysate production enables Tablo to serve as a dialysis clinic on wheels, with two-way wireless data transmission and a proprietary data analytics platform powering a new holistic approach to dialysis care.
Studies show patients with end-stage kidney disease (ESKD) are healthier mentally and physically dialyzing at home, more likely to be employed and maintain more control of their daily activities. Yet, just 3% of the ESKD population currently performs home hemodialysis, in large part due to historically complicated systems that made it too difficult to undertake or sustain. Under the multi-year agreement, U.S. Renal Care can utilize Outset’s Tablo Hemodialysis System as a home dialysis option throughout the 33 states in which it provides care. Patients dialyzing with Tablo report that the system is easy to learn and operate in their home. Expanding treatment options in the communities served by U.S. Renal Care will aid in meeting the growing demand of dialysis patients seeking treatment at home.
"Our collaboration with U.S Renal Care is an important step forward in providing dialysis patients with options for where, when and how they want to dialyze.” Outset Medical Board Chair/CEO Leslie Trigg said. “Tablo was specifically designed to reduce the complexity of dialysis and help restore the identity and agency of patients who must dialyze to survive. We are pleased to partner with U.S. Renal Care to advance this mission.”
Tablo is indicated for use from the hospital to the home and aims to transform the dialysis experience for patients and operationally simplify it for providers. Requiring only access to tap water and a standard electrical outlet, Tablo serves as a single enterprise solution that can be utilized across the continuum of care, allowing dialysis to be delivered anytime, anywhere and by anyone.
“We strive to provide patients with new and innovative solutions that deliver the best outcomes possible,” U.S. Renal Care Co-Chief Operating Officer Steve Nottingham stated. “We have seen success using the Tablo system in our home hemodialysis program, and with our multi-year agreement with Outset, can continue providing our patients and caregivers access to lifesaving dialysis treatment in an easy-to-operate system, all in the comfort of their own homes.”
U.S. Renal Care, the largest privately held and fastest-growing U.S. dialysis provider, partners with nephrologists across 500 centers in 33 states to care for thousands of people living with kidney disease nationwide.
Outset Medical is a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis. The Tablo Hemodialysis System, cleared by the U.S. Food and Drug Administration for use from the hospital to the home, serves as a single enterprise solution that can be used across the continuum of care, allowing dialysis to be delivered anytime, anywhere and by anyone. The integration of water purification and on-demand dialysate production enables Tablo to serve as a dialysis clinic on wheels, with two-way wireless data transmission and a proprietary data analytics platform powering a new holistic approach to dialysis care.